The DIAdvisor™ was a large-scale integrating project (IP) aiming at the development of a prediction based advisory system, using past and easily available diabetes relevant information to optimise the therapy of patients with type I and developed type II diabetes. The DIAdvisor™ technology is not dependent on specific sensor technologies and can be adapted to technologies like standard strip sensing, minimally-invasive continuous glucose sensors and emerging non-invasive methods.
Glucose prediction and automated advice is difficult and requires advanced science within the fields of physiological modelling, identification theory, control theory, medical device technology, risk management theory, sensor science and user understanding. Project objectives were only achievable due to a well-balanced group of eminent experts, including academics, clinicians, user representatives and leading companies.
During 2008 to 2012, the project objectives were achieved through systematic collection and exploitation of physiological data leading to effective prediction and advice algorithms. System function was verified in a clinical setting and eventually performance was validated in a randomised crossover clinical trial. The outcome showing significant blood glucose control improvements, was presented by professor Eric Renard at ADA 2013.
The expected impact of a DIAdvisor™ product is improved diabetes control and quality of life in large populations of insulin treated patients, leading to fewer diabetic complications and lower Health Care costs.